Skip to Main content Skip to Navigation
Journal articles

Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Silvia Franceschi 1, * Mauro Lise Christian Trépo 2 Pascale Berthillon 3 Shu-Chun Chuang Alexandra Nieters 4, 5 Ruth C Travis Roel Vermeulen 6 Kim Overvad 7 Anne Tjønneland 8 Anja Olsen 9 Manuela M Bergmann 10 Heiner Boeing 8 Rudolf Kaaks 11 Nikolaus Becker 12 Antonia Trichopoulou 8, 13 Pagona Lagiou 14 Christina Bamia 15 Domenico Palli 16 Sabina Sieri 17 Salvatore Panico 18 Rosario Tumino 19 Carlotta Sacerdote 20 Bas Bueno-De-Mesquita 21, 22 Petra H M Peeters 23, 24 Laudina Rodríguez 25 Leila Luján Barroso Miren Dorronsoro 26 María-José Sánchez 27, 28 Carmen Navarro 29, 30 Aurelio Barricarte 8, 31 Sara Regnér Signe Borgquist 32 Beatrice Melin 33 Göran Hallmans 34 Kay-Tee Khaw 35 Nick Wareham 36 Sabina Rinaldi 37 Pierre Hainaut 38 Elio Riboli 39 Paolo Vineis 40, 41
* Corresponding author
2 E16
IL - IFR Laennec, UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
3 E16
UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
Abstract : BACKGROUND: Case-control studies suggested a moderate, but consistent, association of hepatitis C virus (HCV) infection with lymphoid tissue malignancies, especially non-Hodgkin lymphoma (NHL). More limited data suggested that hepatitis B virus (HBV) infection might also be associated with NHL. However, prospective studies on the topic are few. METHODS: A nested case-control study was conducted in eight countries participating in the EPIC prospective study. Seven hundred thirty-nine incident cases of NHL, 238 multiple myeloma (MM), and 46 Hodgkin lymphoma (HL) were matched with 2,028 controls. Seropositivity to anti-HCV, anti-HBc, and HBsAg was evaluated and conditional logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (CI) for NHL, MM, or HL, and their combination. RESULTS: Anti-HCV seropositivity among controls in different countries ranged from 0% to 5.3%; HBsAg from 0% to 2.7%; and anti-HBc from 1.9% to 45.9%. Similar nonsignificant associations were found with seropositivity to HBsAg for NHL (OR = 1.78; 95% CI: 0.78-4.04), MM (OR = 4.00; 95% CI: 1.00-16.0), and HL (OR = 2.00; 95% CI: 0.13-32.0). The association between HBsAg and the combination of NHL, MM, and HL (OR = 2.21; 95% CI: 1.12-4.33) was similar for cancer diagnosed less than 3 and 3 or more years after blood collection. No significant association was found between anti-HCV and NHL, MM, or HL risk, but the corresponding CIs were very broad. CONCLUSIONS: Chronic HBV infection may increase the risk of lymphoid malignancies among healthy European volunteers. IMPACT: Treatment directed at control of HBV infection should be evaluated in HBsAg-seropositive patients with lymphoid tissue malignancies.
Document type :
Journal articles
Complete list of metadata
Contributor : Marie-Pierre Scanella Connect in order to contact the contributor
Submitted on : Thursday, April 11, 2013 - 2:23:45 PM
Last modification on : Tuesday, October 19, 2021 - 11:07:57 PM

Links full text




Silvia Franceschi, Mauro Lise, Christian Trépo, Pascale Berthillon, Shu-Chun Chuang, et al.. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC).. Cancer Epidemiology, Biomarkers and Prevention, American Association for Cancer Research, 2011, 20 (1), pp.208-14. ⟨10.1158/1055-9965.EPI-10-0889⟩. ⟨hal-00811971⟩



Record views